66 filings
8-K
TSHA
Taysha Gene Therapies Inc
19 Mar 24
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
4:17pm
8-K
TSHA
Taysha Gene Therapies Inc
10 Jan 24
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
12:00am
8-K
TSHA
Taysha Gene Therapies Inc
20 Dec 23
Departure of Directors or Certain Officers
4:21pm
8-K
TSHA
Taysha Gene Therapies Inc
15 Nov 23
Amendments to Articles of Incorporation or Bylaws
4:29pm
8-K
TSHA
Taysha Gene Therapies Inc
14 Nov 23
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:47pm
8-K
1ctb 2s0oicpcoi2kyx
1 Nov 23
Departure of Directors or Certain Officers
4:02pm
8-K
doh4atx8iucklu7juc
26 Sep 23
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
8:08am
8-K
jdw4z0f qubwg
19 Sep 23
Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development
4:09pm
8-K
zk1kbj7rpodf2vvuac5c
29 Aug 23
Other Events
7:00am
8-K
j1uwnla
24 Aug 23
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
8:09am
8-K
6y83zgamm0
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
8-K
etvc06s0 ibbul
4 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:02pm
8-K
7w9 dvwpz
31 Jul 23
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome
8:05am
8-K
eg24v
28 Jun 23
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day
8:31am
8-K
5kttv7a8pu o20
23 Jun 23
Submission of Matters to a Vote of Security Holders
5:27pm
8-K
scmv33b
22 Jun 23
Departure of Directors or Certain Officers
5:12pm
8-K
9imy9heqi
6 Jun 23
Departure of Directors or Certain Officers
4:02pm
8-K
rrozkyx
5 Jun 23
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial
8:20am
8-K
8ni4ie31b5 ux4fs58
19 May 23
Other Events
8:28am
8-K
j5u59bvduu07611
15 May 23
Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:13pm